

Dario Giugliano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6882550/publications.pdf>

Version: 2024-02-01

550
papers

37,551
citations

2963

93
h-index

3903

177
g-index

562
all docs

562
docs citations

562
times ranked

32949
citing authors

#	ARTICLE	IF	CITATIONS
1	Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2022, 13, 619-634.	1.2	17
2	The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. <i>Cardiovascular Diabetology</i> , 2022, 21, 42.	2.7	54
3	Applications for social security benefits related to diabetes in the working age in Italy between 2009 and 2019: a nationwide retrospective cohort study. <i>BMJ Open</i> , 2022, 12, e057825.	0.8	0
4	Quality of life in Klinefelter patients on testosterone replacement therapy compared to healthy controls: an observational study on the impact of psychological distress, personality traits, and coping strategies. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1053-1063.	1.8	8
5	Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 17.	2.7	27
6	The residual cardiorenal risk in type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 36.	2.7	14
7	Sodium-glucose co-transporter 2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1672-1676.	2.2	30
8	Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. <i>Diabetes Care</i> , 2021, 44, 1353-1360.	4.3	22
9	Up and down waves of glycemic control and lower-extremity amputation in diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 135.	2.7	7
10	Simplification of complex insulin therapy: a story of dogma and therapeutic resignation. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108958.	1.1	9
11	GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. <i>Cardiovascular Diabetology</i> , 2021, 20, 189.	2.7	104
12	GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off. <i>Cardiovascular Diabetology</i> , 2021, 20, 205.	2.7	18
13	Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. <i>Cardiovascular Diabetology</i> , 2021, 20, 210.	2.7	31
14	SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. <i>Cardiovascular Diabetology</i> , 2021, 20, 236.	2.7	63
15	From pump to sink: The hydraulic connection of type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2020, 159, 107772.	1.1	0
16	Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti-hyperglycaemic drug matters?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 149-157.	2.2	21
17	Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis. <i>Stroke</i> , 2020, 51, 666-669.	1.0	42
18	Diabetic Foot Problems During the COVID-19 Pandemic in a Tertiary Care Center: The Emergency Among the Emergencies. <i>Diabetes Care</i> , 2020, 43, e123-e124.	4.3	60

#	ARTICLE	IF	CITATIONS
19	Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies. <i>Cardiovascular Diabetology</i> , 2020, 19, 115.	2.7	33
20	Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2020, 43, 1146-1156.	4.3	155
21	Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials. <i>Diabetes Research and Clinical Practice</i> , 2020, 162, 108114.	1.1	29
22	Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney. <i>Cardiovascular Diabetology</i> , 2020, 19, 35.	2.7	24
23	<p>Alterations in the Levels of Circulating and Endothelial Progenitor Cells Levels in Young Adults with Type 1 Diabetes: A 2-Year Follow-Up from the Observational METRO Study</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 777-784.	1.1	4
24	Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1397-1405.	2.2	27
25	GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2576-2580.	2.2	104
26	Relationship between albuminuric CKD and diabetic retinopathy in a real-world setting of type 2 diabetes: Findings from No blind study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 923-930.	1.1	33
27	Metabolic effectiveness of gliflozins and gliptins in the routine clinical practice of patients with type 2 diabetes: preliminary results from GIOIA, a prospective multicentre study. <i>Diabetes Research and Clinical Practice</i> , 2019, 155, 107787.	1.1	3
28	Class effect for SGLT-2 inhibitors: a tale of 9 drugs. <i>Cardiovascular Diabetology</i> , 2019, 18, 94.	2.7	30
29	Beyond basal-bolus insulin regimen: Is it still the ultimate chance for therapy in diabetes?. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107922.	1.1	5
30	The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2019, 154, 101-115.	1.1	19
31	Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. <i>Journal of the American Heart Association</i> , 2019, 8, e012356.	1.6	73
32	Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials. <i>Endocrine</i> , 2019, 65, 15-24.	1.1	25
33	Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 1165-1169.	1.8	28
34	EMPATHY: A New Tool for Identifying the Most Suitable Thyroxine Formulation in Hypothyroid Patients. <i>Thyroid</i> , 2019, 29, 928-933.	2.4	10
35	Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1790-1800.	2.2	28
36	Are gliflozins the new statins for diabetes?. <i>Diabetes Research and Clinical Practice</i> , 2019, 153, 191-193.	1.1	5

#	ARTICLE	IF	CITATIONS
37	Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. <i>Frontiers in Endocrinology</i> , 2019, 10, 45.	1.5	94
38	Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1081-1087.	2.2	39
39	Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 495-503.	1.8	48
40	Dissonance among treatment algorithms for hyperglycemia in type 2 diabetes: an egalitarian dialog. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 237-242.	1.8	2
41	Gender-differences in glycemic control and diabetes related factors in young adults with type 1 diabetes: results from the METRO study. <i>Endocrine</i> , 2018, 61, 240-247.	1.1	19
42	Comment on Edelman and Polonsky. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. <i>Diabetes Care</i> 2017;40:1425-1432. <i>Diabetes Care</i> , 2018, 41, e17-e17.	4.3	5
43	Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. <i>Endocrine</i> , 2018, 61, 23-27.	1.1	36
44	The Effects of Subcutaneous Insulin Infusion Versus Multiple Insulin Injections on Glucose Variability in Young Adults with Type 1 Diabetes: The 2-Year Follow-Up of the Observational METRO Study. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 117-126.	2.4	24
45	From inflammation to sexual dysfunctions: a journey through diabetes, obesity, and metabolic syndrome. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 1249-1258.	1.8	101
46	More sugar? No, thank you! The elusive nature of low carbohydrate diets. <i>Endocrine</i> , 2018, 61, 383-387.	1.1	22
47	TSH oscillations in young patients with type 1 diabetes may be due to glycemic variability. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 389-393.	1.8	9
48	Type 2 diabetes and cardiovascular prevention: the dogmas disputed. <i>Endocrine</i> , 2018, 60, 224-228.	1.1	11
49	Diabetes is a cardiovascular disease, isn't it?. <i>Diabetes Research and Clinical Practice</i> , 2018, 135, 229-231.	1.1	6
50	Metabolic syndrome and cancer: "The common soil hypothesis". <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 389-397.	1.1	70
51	Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2309-2313.	2.2	32
52	Particulate matter air pollution: individual choices for improving cardiometabolic well-being. <i>Endocrine</i> , 2018, 59, 495-498.	1.1	3
53	Influence of occlusal characteristics, food intake and oral hygiene habits on dental caries in adolescents: a cross-sectional study. <i>European Journal of Paediatric Dentistry</i> , 2018, 19, 95-100.	0.4	9
54	Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?. <i>Endocrine</i> , 2017, 55, 360-365.	1.1	27

#	ARTICLE	IF	CITATIONS
55	Premixed insulin regimens in type 2 diabetes: pros. <i>Endocrine</i> , 2017, 55, 45-50.	1.1	7
56	Mediterranean diet for type 2 diabetes: cardiometabolic benefits. <i>Endocrine</i> , 2017, 56, 27-32.	1.1	88
57	Genetics of medullary thyroid cancer: An overview. <i>International Journal of Surgery</i> , 2017, 41, S2-S6.	1.1	89
58	Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. <i>Nutrition Reviews</i> , 2017, 75, 307-326.	2.6	294
59	Pituitary dysfunction in granulomatosis with polyangiitis. <i>Pituitary</i> , 2017, 20, 594-601.	1.6	32
60	Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2017, 40, 614-624.	4.3	97
61	Insights into the relationships between diabetes, prediabetes, and cancer. <i>Endocrine</i> , 2017, 56, 231-239.	1.1	63
62	Natural history of autoimmune primary ovarian insufficiency in patients with Addison's disease: from normal ovarian function to overt ovarian dysfunction. <i>European Journal of Endocrinology</i> , 2017, 177, 329-337.	1.9	8
63	Effect of a Mediterranean diet on endothelial progenitor cells and carotid intima-media thickness in type 2 diabetes: Follow-up of a randomized trial. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 399-408.	0.8	59
64	Can diet prevent diabetes?. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 288-290.	1.2	10
65	Influence of short-term selenium supplementation on the natural course of Hashimoto's thyroiditis: clinical results of a blinded placebo-controlled randomized prospective trial. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 83-89.	1.8	58
66	Sexual function in young women with type 1 diabetes: the METRO study. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 169-177.	1.8	36
67	Erectile dysfunction in young men with type 1 diabetes. <i>International Journal of Impotence Research</i> , 2017, 29, 17-22.	1.0	30
68	Intensive Lifestyle Intervention for Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2494.	3.8	1
69	Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In <i>Standards of Medical Care in Diabetes</i> 2016. <i>Diabetes Care</i> 2016;39(Suppl. 1):S52-S59. <i>Diabetes Care</i> , 2016, 39, e86-e87.	4.3	16
70	Mediterranean diet cools down the inflammatory milieu in type 2 diabetes: the MÃ% DITA randomized controlled trial. <i>Endocrine</i> , 2016, 54, 634-641.	1.1	43
71	Personalized intensification of insulin therapy in type 2 diabetes - does a basal-bolus regimen suit all patients?. <i>Current Medical Research and Opinion</i> , 2016, 32, 1425-1434.	0.9	6
72	Effects of Mediterranean diet on sexual function in people with newly diagnosed type 2 diabetes: The MÃ DITA trial. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1519-1524.	1.2	60

#	ARTICLE	IF	CITATIONS
73	Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects. <i>Pituitary</i> , 2016, 19, 625-642.	1.6	94
74	Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 77-83.	1.0	27
75	Comment on Mita et al. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial. <i>Diabetes Care</i> 2016;39:455-464. <i>Diabetes Care</i> , 2016, 39, e102-e103.	4.3	3
76	Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. <i>Endocrine</i> , 2016, 54, 32-37.	1.1	1
77	Primary Prevention of Sexual Dysfunction With Mediterranean Diet in Type 2 Diabetes: The MÃ^DITA Randomized Trial. <i>Diabetes Care</i> , 2016, 39, e143-e144.	4.3	22
78	Particulate matter pollutants and risk of type 2 diabetes: a time for concern?. <i>Endocrine</i> , 2016, 51, 32-37.	1.1	54
79	Sexual dysfunction in women with cancer: a systematic review with meta-analysis of studies using the Female Sexual Function Index. <i>Endocrine</i> , 2016, 54, 329-341.	1.1	84
80	Serum but not salivary cortisol levels are influenced by daily glycemic oscillations in type 2 diabetes. <i>Endocrine</i> , 2016, 53, 220-226.	1.1	19
81	Anti-inflammatory Effect of Mediterranean Diet in Type 2 Diabetes Is Durable: 8-Year Follow-up of a Controlled Trial. <i>Diabetes Care</i> , 2016, 39, e44-e45.	4.3	23
82	Longitudinal behavior of autoimmune GH deficiency: from childhood to transition age. <i>European Journal of Endocrinology</i> , 2016, 174, 381-387.	1.9	15
83	Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Endocrine</i> , 2016, 51, 417-428.	1.1	68
84	Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study. <i>Endocrine</i> , 2016, 52, 244-252.	1.1	30
85	Increased platelet reactivity in Klinefelter men: something new to consider. <i>Andrology</i> , 2015, 3, 876-881.	1.9	23
86	Comment on Krul-Poel et al. Effect of Vitamin D Supplementation on Glycemic Control in Patients With Type 2 Diabetes (SUNNY Trial): A Randomized Placebo-Controlled Trial. <i>Diabetes Care</i> 2015;38:1420-1426. <i>Diabetes Care</i> , 2015, 38, e168-e168.	4.3	0
87	A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. <i>BMJ Open</i> , 2015, 5, e008222.	0.8	368
88	Vitamin D and autoimmunity: what happens in autoimmune polyendocrine syndromes?. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 629-633.	1.8	24
89	Circulating endothelial progenitor cells in type 1 diabetic patients with erectile dysfunction. <i>Endocrine</i> , 2015, 49, 415-421.	1.1	21
90	Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither?. <i>Endocrine</i> , 2015, 50, 56-60.	1.1	6

#	ARTICLE	IF	CITATIONS
91	Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: A population-based study. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 157-163.	1.1	39
92	A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. <i>BMJ Open</i> , 2015, 5, e005892-e005892.	0.8	63
93	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3231-3244.	1.8	113
94	Linking prediabetes and cancer: a complex issue. <i>Diabetologia</i> , 2015, 58, 201-202.	2.9	4
95	Premature Ejaculation is Associated with Glycemic Control in Type 1 Diabetes. <i>Journal of Sexual Medicine</i> , 2015, 12, 93-99.	0.3	18
96	Glucose variability inversely associates with endothelial progenitor cells in type 1 diabetes. <i>Endocrine</i> , 2015, 48, 342-345.	1.1	14
97	Peripheral Arterial Disease and Cardiovascular Risk. <i>Angiology</i> , 2015, 66, 708-710.	0.8	5
98	Remission of type 2 diabetes: is bariatric surgery ready for prime time?. <i>Endocrine</i> , 2015, 48, 417-421.	1.1	23
99	Comment on Tay et al. A Very Low-Carbohydrate, Low-Saturated Fat Diet for Type 2 Diabetes Management: A Randomized Trial. <i>Diabetes Care</i> 2014;37:2909-2918. <i>Diabetes Care</i> , 2015, 38, e64-e64.	4.3	2
100	Rituximab-induced remission of autoimmune hypophysitis and primary immune thrombocytopenia in a patient with autoimmune polyendocrine syndrome type 4. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 313-317.	1.2	7
101	Comment on Grunberger "Insulin Analogs" Are They Worth It? Yes! and Davidson "Insulin Analogs" Is There a Compelling Case to Use Them? No! <i>Diabetes Care</i> 2014;37:1771-1774. <i>Diabetes Care</i> , 2014, 37, e229-e230.	4.3	3
102	Comment on Khunti et al. Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More Than 80,000 People. <i>Diabetes Care</i> 2013;36:3411-3417. <i>Diabetes Care</i> , 2014, 37, e113-e113.	4.3	2
103	Comment on Home et al. Predictive and Explanatory Factors of Change in HbA1c in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs. <i>Diabetes Care</i> 2014;37:1237-1245. <i>Diabetes Care</i> , 2014, 37, e183-e183.	4.3	2
104	Vitamin D Deficiency in Type 2 Diabetic Patients with Hypogonadism. <i>Journal of Sexual Medicine</i> , 2014, 11, 536-542.	0.3	24
105	Mediterranean diet and type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2014, 30, 34-40.	1.7	66
106	Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. <i>BMJ Open</i> , 2014, 4, e005442-e005442.	0.8	56
107	The Association Between Metabolic Syndrome and Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 742-743.	1.1	2
108	A nomogram to estimate the proportion of patients at hemoglobin A1c target $\leq 7\%$ with noninsulin antidiabetic drugs in type 2 diabetes: a systematic review of 137 randomized controlled trials with 39 845 patients. <i>Acta Diabetologica</i> , 2014, 51, 305-311.	1.2	8

#	ARTICLE	IF	CITATIONS
109	Metabolic syndrome and endometrial cancer: a meta-analysis. <i>Endocrine</i> , 2014, 45, 28-36.	1.1	123
110	Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. <i>Endocrine</i> , 2014, 46, 39-42.	1.1	22
111	Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors. <i>Endocrine</i> , 2014, 46, 43-51.	1.1	44
112	New guidelines for metabolic targets in diabetes: clinician's opinion does matter. <i>Endocrine</i> , 2014, 46, 431-434.	1.1	5
113	Healthy lifestyle for metabolic health: no more excuse!. <i>Endocrine</i> , 2014, 46, 176-178.	1.1	14
114	Metabolic syndrome and cancer: holistic or reductionist?. <i>Endocrine</i> , 2014, 45, 362-364.	1.1	31
115	Characterization of pituitary cells targeted by antipituitary antibodies in patients with isolated autoimmune diseases without pituitary insufficiency may help to foresee the kind of future hypopituitarism. <i>Pituitary</i> , 2014, 17, 457-463.	1.6	17
116	The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 799-808.	1.4	19
117	Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI. <i>Endocrine</i> , 2014, 46, 256-262.	1.1	32
118	Which diet for prevention of type 2 diabetes? A meta-analysis of prospective studies. <i>Endocrine</i> , 2014, 47, 107-116.	1.1	112
119	Cardiovascular guidelines: separate career may help attenuate controversy. <i>Cardiovascular Diabetology</i> , 2014, 13, 66.	2.7	2
120	The effect of Mediterranean diet on the development of type 2 diabetes mellitus: A meta-analysis of 10 prospective studies and 136,846 participants. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 903-911.	1.5	194
121	Initiation and Gradual Intensification of Premixed Insulin Lispro Therapy Versus Basal ± Mealtime Insulin in Patients With Type 2 Diabetes Eating Light Breakfasts. <i>Diabetes Care</i> , 2014, 37, 372-380.	4.3	16
122	The Effects of a Mediterranean Diet on the Need for Diabetes Drugs and Remission of Newly Diagnosed Type 2 Diabetes: Follow-up of a Randomized Trial. <i>Diabetes Care</i> , 2014, 37, 1824-1830.	4.3	149
123	Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. <i>Endocrine</i> , 2013, 44, 634-647.	1.1	152
124	Should we abandon statins in the prevention of bone fractures?. <i>Endocrine</i> , 2013, 44, 326-333.	1.1	31
125	Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes?. <i>Endocrine</i> , 2013, 44, 343-345.	1.1	20
126	Mediterranean diet and metabolic syndrome: An updated systematic review. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2013, 14, 255-263.	2.6	106

#	ARTICLE	IF	CITATIONS
127	Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2346-2350.	4.3	158
128	Mediterranean Diet for Primary Prevention of Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2013, 369, 672-677.	13.9	119
129	Fracture Risk and Bone Mineral Density in Metabolic Syndrome: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3306-3314.	1.8	30
130	Effect of metabolic syndrome and its components on prostate cancer risk: Meta-analysis. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 132-139.	1.8	112
131	Anti-Pituitary Antibodies and Hypogonadotropic Hypogonadism in Type 2 Diabetes: In Search of a Role. <i>Diabetes Care</i> , 2013, 36, e116-e117.	4.3	13
132	Comment on: Raz et al. Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> 2013;36:1779-1788. <i>Diabetes Care</i> , 2013, 36, e192-e192.	4.3	1
133	Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. <i>Diabetes Care</i> 2013;36:2915-2922. <i>Diabetes Care</i> , 2013, 36, e180-e180.	4.3	3
134	Metabolic syndrome and postmenopausal breast cancer. <i>Menopause</i> , 2013, 20, 1301-1309.	0.8	110
135	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. <i>Drug Design, Development and Therapy</i> , 2013, 7, 989.	2.0	41
136	Circulating endothelial progenitor cells in acromegaly. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 825-30.	1.8	4
137	Comment on: Wheeler et al. Macronutrients, Food Groups, and Eating Patterns in the Management of Diabetes: A Systematic Review of the Literature, 2010. <i>Diabetes Care</i> 2012;35:434-445. <i>Diabetes Care</i> , 2012, 35, e51-e51.	4.3	4
138	Basal Supplementation of Insulin Lispro Protamine Suspension Versus Insulin Glargine and Detemir for Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2698-2705.	4.3	11
139	Review: lifestyle modifications and pharmacotherapy for cardiovascular risk factors are associated with improvements in erectile dysfunction. <i>Evidence-based Nursing</i> , 2012, 15, 71-72.	0.1	1
140	Humalog (lispro) for type 2 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1541-1550.	1.4	10
141	Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 209-221.	1.4	18
142	Lifestyle for Erectile Dysfunction: A Good Choice. <i>Archives of Internal Medicine</i> , 2012, 172, 296.	4.3	3
143	Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2012, 3, 99-108.	1.4	5
144	Evidence That Hyperglycemia After Recovery From Hypoglycemia Worsens Endothelial Function and Increases Oxidative Stress and Inflammation in Healthy Control Subjects and Subjects With Type 1 Diabetes. <i>Diabetes</i> , 2012, 61, 2993-2997.	0.3	136

#	ARTICLE	IF	CITATIONS
145	HbA1c targets for type 2 diabetes: How many, – how far!. <i>Diabetes Research and Clinical Practice</i> , 2012, 96, 414-415.	1.1	6
146	Diabetes medications and cancer: A way out of uncertainty. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 175-177.	1.1	3
147	Lifestyle and metabolic approaches to maximizing erectile and vascular health. <i>International Journal of Impotence Research</i> , 2012, 24, 61-68.	1.0	52
148	Metabolic Syndrome and Risk of Cancer. <i>Diabetes Care</i> , 2012, 35, 2402-2411.	4.3	900
149	Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 228-233.	2.2	119
150	Increased consumption of green leafy vegetables, but not fruit, vegetables or fruit and vegetables combined, is associated with reduced incidence of type 2 diabetes. <i>Evidence-Based Medicine</i> , 2011, 16, 27-28.	0.6	12
151	Lifestyle/Dietary Recommendations for Erectile Dysfunction and Female Sexual Dysfunction. <i>Urologic Clinics of North America</i> , 2011, 38, 293-301.	0.8	21
152	The Effect of Mediterranean Diet on Metabolic Syndrome and its Components. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1299-1313.	1.2	917
153	Mediterranean Diet and Weight Loss: Meta-Analysis of Randomized Controlled Trials. <i>Metabolic Syndrome and Related Disorders</i> , 2011, 9, 1-12.	0.5	275
154	Clinical Inertia as a Clinical Safeguard. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1591.	3.8	74
155	Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review. <i>Diabetes Research and Clinical Practice</i> , 2011, 92, 1-10.	1.1	50
156	Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes-a randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 439-445.	2.2	63
157	Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 594-603.	2.2	92
158	Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 1149-1157.	2.2	12
159	Relationship of baseline HbA_{1c} and HbA_{1c} reduction following insulin therapy in Type–2 diabetes. <i>Diabetic Medicine</i> , 2011, 28, 247-247.	1.2	2
160	Relationship of baseline HbA1c, HbA1c change and HbA1c target of <7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials. <i>International Journal of Clinical Practice</i> , 2011, 65, 602-612.	0.8	30
161	Obesity, the Metabolic Syndrome, and Sexual Dysfunction in Men. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 169-173.	2.3	55
162	Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review. <i>Journal of Diabetes and Its Complications</i> , 2011, 25, 275-281.	1.2	17

#	ARTICLE	IF	CITATIONS
163	GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2011, 27, 1519-1528.	0.9	44
164	The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an "Endothelial Resistance" to Glucagon-Like Peptide 1 in Diabetes. <i>Diabetes Care</i> , 2011, 34, 697-702.	4.3	119
165	When Metformin Fails in Type 2 Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2011, 171, 365.	4.3	14
166	Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 510-517.	4.3	116
167	Clinical Inertia and Uncertainty in Medicine"Reply. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 383.	3.8	6
168	Long-Term Effect of Mediterranean-Style Diet and Calorie Restriction on Biomarkers of Longevity and Oxidative Stress in Overweight Men. <i>Cardiology Research and Practice</i> , 2011, 2011, 1-5.	0.5	37
169	Cardiovascular Disease-Related Lifestyle Factors and Longevity. <i>Cardiology Research and Practice</i> , 2011, 2011, 1-2.	0.5	3
170	A (hi)story pour les analphabtes" of Larissa Sansour's video. <i>Third Text</i> , 2011, 25, 301-309.	0.3	0
171	Insulin Analogs and Glycosylated Hemoglobin Target of Less Than 7% in Type 2 Diabetes: A Systematic Review of Randomized Trials. <i>Metabolic Syndrome and Related Disorders</i> , 2011, 9, 167-176.	0.5	2
172	Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in Type 2 diabetic patients with different characteristics. <i>Diabetic Medicine</i> , 2010, 27, 911-917.	1.2	25
173	Effects of a Mediterranean-Style Diet on the Need for Antihyperglycemic Drug Therapy in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Trial. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 379-380.	0.2	5
174	Original Research"Outcomes Assessment: Development and Validation of a 6-Item Version of the Female Sexual Function Index (FSFI) as a Diagnostic Tool for Female Sexual Dysfunction. <i>Journal of Sexual Medicine</i> , 2010, 7, 1139-1146.	0.3	215
175	ORIGINAL RESEARCH"ERECTILE DYSFUNCTION: Adherence to Mediterranean Diet and Erectile Dysfunction in Men with Type 2 Diabetes. <i>Journal of Sexual Medicine</i> , 2010, 7, 1911-1917.	0.3	49
176	ORIGINAL RESEARCH"WOMEN'S SEXUAL HEALTH: Adherence to Mediterranean Diet and Sexual Function in Women with Type 2 Diabetes. <i>Journal of Sexual Medicine</i> , 2010, 7, 1883-1890.	0.3	44
177	Dietary Factors, Mediterranean Diet and Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2010, 7, 2338-2345.	0.3	58
178	Determinants of female sexual dysfunction in type 2 diabetes. <i>International Journal of Impotence Research</i> , 2010, 22, 179-184.	1.0	144
179	Adding Noninsulin Antidiabetic Drugs to Metformin Therapy for Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 405.	3.8	0
180	Dietary Glycemic Index and Glycemic Load Are Associated with Metabolic Control in Type 2 Diabetes: The CAPRI Experience. <i>Metabolic Syndrome and Related Disorders</i> , 2010, 8, 255-261.	0.5	14

#	ARTICLE	IF	CITATIONS
181	Effects of a Mixed Meal on Hemodynamics and Autonomic Control of the Heart in Patients with Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 194-200.	1.8	10
182	Lifestyle and Adiponectin Level: Four-Year Follow-up of Controlled Trials. <i>Archives of Internal Medicine</i> , 2010, 170, 1270.	4.3	4
183	Prevention of Type 2 Diabetes by Dietary Patterns: A Systematic Review of Prospective Studies and Meta-Analysis. <i>Metabolic Syndrome and Related Disorders</i> , 2010, 8, 471-476.	0.5	109
184	Determinants of erectile dysfunction in type 2 diabetes. <i>International Journal of Impotence Research</i> , 2010, 22, 204-209.	1.0	141
185	Prevention and control of type 2 diabetes by Mediterranean diet: A systematic review. <i>Diabetes Research and Clinical Practice</i> , 2010, 89, 97-102.	1.1	170
186	Interleukin-20 circulating levels in obese women: Effect of weight loss. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 180-185.	1.1	18
187	Olive oil and health: Summary of the II international conference on olive oil and health consensus report, Ja�n and C�rdoba (Spain) 2008. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 284-294.	1.1	449
188	Mediterranean Diet and the Metabolic Syndrome: The End of the Beginning. <i>Metabolic Syndrome and Related Disorders</i> , 2010, 8, 197-200.	0.5	33
189	Characterization of a Novel Polymorphism in PPARC Regulatory Region Associated with Type 2 Diabetes and Diabetic Retinopathy in Italy. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-7.	3.0	36
190	Which Mediterranean Diet in the Management of Metabolic Syndrome?. <i>Archives of Internal Medicine</i> , 2009, 169, 1069.	4.3	0
191	Low-Carbohydrate Diet and Blood Lipid Levels: How Good and How Fast?. <i>Archives of Internal Medicine</i> , 2009, 169, 1930.	4.3	0
192	Long-Term Glycemic Control Influences the Long-Lasting Effect of Hyperglycemia on Endothelial Function in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2751-2756.	1.8	57
193	Effects of Intensive Lifestyle Changes on Erectile Dysfunction in Men. <i>Journal of Sexual Medicine</i> , 2009, 6, 243-250.	0.3	103
194	Circulating CD34+KDR+ Endothelial Progenitor Cells Correlate with Erectile Function and Endothelial Function in Overweight Men. <i>Journal of Sexual Medicine</i> , 2009, 6, 107-114.	0.3	60
195	Hyperlipidemia and Sexual Function in Premenopausal Women. <i>Journal of Sexual Medicine</i> , 2009, 6, 1696-1703.	0.3	45
196	Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?. <i>Acta Diabetologica</i> , 2009, 46, 173-181.	1.2	22
197	Which diet is best for diabetes?. <i>Diabetologia</i> , 2009, 52, 988-989.	2.9	5
198	Adherence to a Mediterranean diet and glycaemic control in Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2009, 26, 900-907.	1.2	84

#	ARTICLE	IF	CITATIONS
199	Simultaneous control of hyperglycemia and oxidative stress normalizes enhanced thrombin generation in type 2 diabetes. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1228-1230.	1.9	13
200	Effects of a Mediterranean-Style Diet on the Need for Antihyperglycemic Drug Therapy in Patients With Newly Diagnosed Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2009, 151, 306.	2.0	380
201	Lifestyle approach for type 2 diabetes and metabolic syndrome. <i>Current Atherosclerosis Reports</i> , 2008, 10, 523-528.	2.0	20
202	Phenotypic Assessment of Endothelial Microparticles in Diabetic and Nondiabetic Men with Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2008, 5, 1436-1442.	0.3	41
203	Defining the Role of Insulin Lispro in the Management of Postprandial Hyperglycaemia in Patients with Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2008, 28, 199-210.	1.1	8
204	Glucose "peak" and glucose "spike" Impact on endothelial function and oxidative stress. <i>Diabetes Research and Clinical Practice</i> , 2008, 82, 262-267.	1.1	90
205	Post-Meal Glucose Peaks at Home Associate with Carotid Intima-Media Thickness in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1345-1350.	1.8	152
206	Obesity and sexual dysfunction, male and female. <i>International Journal of Impotence Research</i> , 2008, 20, 358-365.	1.0	126
207	Mediterranean Diet Inversely Associated With the Incidence of Metabolic Syndrome: the SUN Prospective Cohort: Response to Tortosa et al.. <i>Diabetes Care</i> , 2008, 31, e36-e36.	4.3	3
208	Addition of Neutral Protamine Lispro Insulin or Insulin Glargine to Oral Type 2 Diabetes Regimens for Patients with Suboptimal Glycemic Control. <i>Annals of Internal Medicine</i> , 2008, 149, 531.	2.0	49
209	Mediterranean dietary patterns and chronic diseases. <i>American Journal of Clinical Nutrition</i> , 2008, 88, 1179-1180.	2.2	6
210	Are there specific treatments for the metabolic syndrome?. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 8-11.	2.2	68
211	Glucose metabolism and hyperglycemia. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 217S-222S.	2.2	184
212	Mediterranean diet and metabolic diseases. <i>Current Opinion in Lipidology</i> , 2008, 19, 63-68.	1.2	175
213	Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients. <i>Diabetes</i> , 2008, 57, 1349-1354.	0.3	977
214	Association of body weight with sexual function in women. <i>International Journal of Impotence Research</i> , 2007, 19, 353-357.	1.0	205
215	Endothelial microparticles correlate with erectile dysfunction in diabetic men. <i>International Journal of Impotence Research</i> , 2007, 19, 161-166.	1.0	52
216	Telmisartan Shows an Equivalent Effect of Vitamin C in Further Improving Endothelial Dysfunction After Glycemia Normalization in Type 1 Diabetes. <i>Diabetes Care</i> , 2007, 30, 1694-1698.	4.3	46

#	ARTICLE	IF	CITATIONS
217	Low-Carbohydrate Diet and Coronary Heart Disease in Women. <i>New England Journal of Medicine</i> , 2007, 356, 750-752.	13.9	18
218	Mediterranean diet improves sexual function in women with the metabolic syndrome. <i>International Journal of Impotence Research</i> , 2007, 19, 486-491.	1.0	58
219	Pioglitazone vs Glimepiride and Carotid Intima-Media Thickness. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1315.	3.8	1
220	Simultaneous Control of Hyperglycemia and Oxidative Stress Normalizes Endothelial Function in Type 1 Diabetes. <i>Diabetes Care</i> , 2007, 30, 649-654.	4.3	92
221	Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: Role of tumor necrosis factor- α . <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 274-279.	1.1	56
222	Diet and the Metabolic Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2007, 5, 291-296.	0.5	34
223	Mediterranean diet and the metabolic syndrome. <i>Molecular Nutrition and Food Research</i> , 2007, 51, 1268-1274.	1.5	62
224	Quantitative Sensory and Autonomic Testing in Nondiabetic Women with Sexual Dysfunction. <i>Journal of Sexual Medicine</i> , 2007, 4, 1367-1372.	0.3	17
225	Mediterranean diet, endothelial function and vascular inflammatory markers. <i>Public Health Nutrition</i> , 2006, 9, 1073-1076.	1.1	75
226	Re: Prevalence and Risk Factors for Female Sexual Dysfunction in Turkish Women. <i>Journal of Urology</i> , 2006, 176, 840-841.	0.2	6
227	The Effects of Diet on Inflammation. <i>Journal of the American College of Cardiology</i> , 2006, 48, 677-685.	1.2	654
228	Virgin Olive Oil and Vegetables Improve Endothelial Health. <i>Journal of the American College of Cardiology</i> , 2006, 48, 413-414.	1.2	2
229	Diet and inflammation: a link to metabolic and cardiovascular diseases. <i>European Heart Journal</i> , 2006, 27, 15-20.	1.0	187
230	Oxidative stress in the metabolic syndrome. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 791-795.	1.8	80
231	Statins, Diet, and Low Cholesterol. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2479.	3.8	0
232	Whole-grain intake cools down inflammation. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 1440-1441.	2.2	18
233	Is the whole-diet approach better than a low-fat diet in cardiovascular risk reduction?. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 921.	2.2	1
234	What to 'eat and chew' in acute myocardial infarction?: reply. <i>European Heart Journal</i> , 2006, 27, 1629-1630.	1.0	3

#	ARTICLE	IF	CITATIONS
235	Role of Adipokines in the Obesity???Inflammation Relationship: The Effect of Fat Removal. Plastic and Reconstructive Surgery, 2006, 118, 1048-1057.	0.7	72
236	Dietary factors in erectile dysfunction. International Journal of Impotence Research, 2006, 18, 370-374.	1.0	48
237	Mediterranean diet improves erectile function in subjects with the metabolic syndrome. International Journal of Impotence Research, 2006, 18, 405-410.	1.0	133
238	Endothelial Microparticles Correlate with Endothelial Dysfunction in Obese Women. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3676-3679.	1.8	140
239	Optimal Treatments for the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, e30.	1.1	3
240	Rosiglitazone Cools Down Inflammation in the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1413-1414.	1.1	15
241	Pioglitazone Reduces Endothelial Microparticles in the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1926-1926.	1.1	35
242	The Ubiquitin-Proteasome System and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Rosiglitazone Treatment. Diabetes, 2006, 55, 622-632.	0.3	112
243	Sexual dysfunction and the Mediterranean diet. Public Health Nutrition, 2006, 9, 1118-1120.	1.1	23
244	Beneficial Effects of a Dietary Approaches to Stop Hypertension Eating Plan on Features of the Metabolic Syndrome: Response to Azdbakht et al.. Diabetes Care, 2006, 29, 954-955.	4.3	14
245	Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care, 2006, 29, 1071-6.	4.3	39
246	The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al. Diabetes Care, 2006, 29, 175-6; author reply 177-8.	4.3	0
247	Mediterranean Diet and Cardiovascular Health. Annals of the New York Academy of Sciences, 2005, 1056, 253-260.	1.8	42
248	The metabolic syndrome: a cause of sexual dysfunction in women. International Journal of Impotence Research, 2005, 17, 224-226.	1.0	96
249	Obesity, the metabolic syndrome, and sexual dysfunction. International Journal of Impotence Research, 2005, 17, 391-398.	1.0	177
250	Inflammation Warms Up the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, e143.	1.1	40
251	Hyperglycemia in Streptozotocin-Induced Diabetic Rat Increases Infarct Size Associated With Low Levels of Myocardial HO-1 During Ischemia/Reperfusion. Diabetes, 2005, 54, 803-810.	0.3	125
252	Fitness Versus Fatness: the Debate Continues. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, e20-1; author reply e20-1.	1.1	6

#	ARTICLE	IF	CITATIONS
253	Effect of Atorvastatin and Irbesartan, Alone and in Combination, on Postprandial Endothelial Dysfunction, Oxidative Stress, and Inflammation in Type 2 Diabetic Patients. <i>Circulation</i> , 2005, 111, 2518-2524.	1.6	281
254	Letter Regarding Article by Ferriera et al, "Postprandial Hypertriglyceridemia Increases Circulating Levels of Endothelial Cell Microparticles". <i>Circulation</i> , 2005, 111, e457-8; author reply e457-8.	1.6	0
255	Acute Pressor and Hormonal Effects of $\hat{1}^2$ -Endorphin at High Doses in Healthy and Hypertensive Subjects: Role of Opioid Receptor Agonism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5167-5174.	1.8	28
256	Resting Metabolic Rate and Respiratory Quotient in Human Longevity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 409-413.	1.8	45
257	High Proportions of Erectile Dysfunction in Men With the Metabolic Syndrome. <i>Diabetes Care</i> , 2005, 28, 1201-1203.	4.3	231
258	Sexual Dysfunction in Women With the Metabolic Syndrome. <i>Diabetes Care</i> , 2005, 28, 756-756.	4.3	35
259	Effect of rimonabant on weight reduction and cardiovascular risk. <i>Lancet, The</i> , 2005, 366, 367-368.	6.3	15
260	Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. <i>American Journal of Hypertension</i> , 2005, 18, 308-318.	1.0	69
261	Oral Amino Acid Administration Decreases Oxidative Stress and Improves Brachial Reactivity in Elderly Individuals. <i>American Journal of Hypertension</i> , 2005, 18, 858-863.	1.0	6
262	Metabolic Effects of Liposuction " Yes or No?. <i>New England Journal of Medicine</i> , 2004, 351, 1354-1357.	13.9	23
263	Effect of Postprandial Hypertriglyceridemia and Hyperglycemia on Circulating Adhesion Molecules and Oxidative Stress Generation and the Possible Role of Simvastatin Treatment. <i>Diabetes</i> , 2004, 53, 701-710.	0.3	335
264	Absence of Inducible Nitric Oxide Synthase Reduces Myocardial Damage During Ischemia Reperfusion in Streptozotocin-Induced Hyperglycemic Mice. <i>Diabetes</i> , 2004, 53, 454-462.	0.3	85
265	Effect of a Mediterranean-Style Diet on Endothelial Dysfunction and Markers of Vascular Inflammation in the Metabolic Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 1440.	3.8	1,819
266	Effect of Lifestyle Changes on Erectile Dysfunction in Obese Men. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2978.	3.8	732
267	Expression of Angiogenic Factors During Acute Coronary Syndromes in Human Type 2 Diabetes. <i>Diabetes</i> , 2004, 53, 2383-2391.	0.3	108
268	Impairment of Coronary Circulation by Acute Hyperhomocysteinemia in Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2004, 27, 2055-2056.	4.3	12
269	Effect of Weight Loss on Cardiac Synchronization and Proinflammatory Cytokines in Premenopausal Obese Women. <i>Diabetes Care</i> , 2004, 27, 47-52.	4.3	212
270	Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans. <i>European Journal of Endocrinology</i> , 2004, 150, 195-200.	1.9	76

#	ARTICLE	IF	CITATIONS
271	Plasma Interleukin-18 Concentrations Are Elevated in Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 272-272.	4.3	32
272	Impairment of coronary circulation by acute hyperhomocysteinaemia and reversal by antioxidant vitamins. <i>Journal of Internal Medicine</i> , 2004, 256, 398-405.	2.7	13
273	Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1453-1459.	1.9	170
274	M40403 prevents myocardial injury induced by acute hyperglycaemia in perfused rat heart. <i>European Journal of Pharmacology</i> , 2004, 497, 65-74.	1.7	24
275	Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients. <i>Diabetologia</i> , 2004, 47, 1535-1540.	2.9	26
276	Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 665-669.	1.8	130
277	Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2004, 110, 214-219.	1.6	406
278	Acute effects of β^2 -endorphin on cardiovascular function in patients with mild to moderate chronic heart failure. <i>American Heart Journal</i> , 2004, 148, 530.	1.2	27
279	Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. <i>American Journal of Hypertension</i> , 2004, 17, 223-227.	1.0	77
280	The metabolic syndrome and inflammation: association or causation?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 228-232.	1.1	185
281	Sympathovagal Balance, Nighttime Blood Pressure, and QT Intervals in Normotensive Obese Women. <i>Obesity</i> , 2003, 11, 653-659.	4.0	40
282	Effect of a multidisciplinary program of weight reduction on endothelial functions in obese women. <i>Journal of Endocrinological Investigation</i> , 2003, 26, RC5-RC8.	1.8	41
283	Effects of Stress Hyperglycemia on Acute Myocardial Infarction: Role of inflammatory immune process in functional cardiac outcome. <i>Diabetes Care</i> , 2003, 26, 3129-3135.	4.3	153
284	Association of Low Interleukin-10 Levels with the Metabolic Syndrome in Obese Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1055-1058.	1.8	281
285	Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese Women. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 1799.	3.8	1,275
286	Morning Blood Pressure Peak, QT Intervals, and Sympathetic Activity in Hypertensive Patients. <i>Hypertension</i> , 2003, 41, 237-243.	1.3	79
287	Effect of High Glucose on Vasculature. <i>Circulation</i> , 2003, 108, e74; author reply e74.	1.6	2
288	Stress Hyperglycemia, Inflammation, and Cardiovascular Events. <i>Diabetes Care</i> , 2003, 26, 1650-1651.	4.3	22

#	ARTICLE	IF	CITATIONS
289	The Effect of Weight Loss on Endothelial Functions in Obesity: Response to Sciacqua et al.. Diabetes Care, 2003, 26, 2968-2969.	4.3	7
290	Cytokine Milieu Tends Toward Inflammation in Type 2 Diabetes. Diabetes Care, 2003, 26, 1647-1647.	4.3	87
291	Effect of dietary antioxidants on postprandial endothelial dysfunction induced by a high-fat meal in healthy subjects. American Journal of Clinical Nutrition, 2003, 77, 139-143.	2.2	112
292	Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. American Journal of Clinical Nutrition, 2003, 78, 1135-1140.	2.2	205
293	Acute Hyperglycemia Induces Nitrotyrosine Formation and Apoptosis in Perfused Heart From Rat. Diabetes, 2002, 51, 1076-1082.	0.3	256
294	LL-Paraoxonase Genotype Is Associated with a More Severe Degree of Homeostasis Model Assessment IR in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 222-225.	1.8	35
295	Reduction of Inflammatory Cytokine Concentrations and Improvement of Endothelial Functions in Obese Women After Weight Loss Over One Year. Circulation, 2002, 105, 804-809.	1.6	932
296	Weight Loss Reduces Interleukin-18 Levels in Obese Women. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3864-3866.	1.8	218
297	FFAs and QT Intervals in Obese Women with Visceral Adiposity: Effects of Sustained Weight Loss Over 1 Year. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2080-2083.	1.8	59
298	Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans. Circulation, 2002, 106, 2067-2072.	1.6	1,717
299	Mediterranean diet and prevention of coronary heart disease. Journal of Endocrinological Investigation, 2002, 25, 296-299.	1.8	9
300	Hyperglycemia and heart dysfunction: An oxidant mechanism contributing to heart failure in diabetes. Journal of Endocrinological Investigation, 2002, 25, 485-488.	1.8	6
301	Autonomic dysfunction associates with prolongation of QT intervals and blunted night BP in obese women with visceral obesity. Journal of Endocrinological Investigation, 2002, 25, RC32-RC35.	1.8	24
302	Elevated plasma free fatty acid concentrations do not modify cardiac repolarization in patients treated by electrolyte-glucose-insulin infusion. Journal of Endocrinological Investigation, 2002, 25, RC19-RC22.	1.8	21
303	Obesity, cytokines and endothelial dysfunction: A link for the raised cardiovascular risk associated with visceral obesity. Journal of Endocrinological Investigation, 2002, 25, 646-649.	1.8	32
304	Simvastatin normalizes QTc dispersion and reduces ventricular electrical instability in isolated hypercholesterolemia. Journal of Endocrinological Investigation, 2002, 25, RC16-RC18.	1.8	11
305	Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: Role of fat and carbohydrate meals. Journal of the American College of Cardiology, 2002, 39, 1145-1150.	1.2	503
306	Endothelin-1 receptor antagonists reduce cardiac electrical instability induced by high glucose in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 366, 193-197.	1.4	7

#	ARTICLE	IF	CITATIONS
307	Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1. <i>Diabetologia</i> , 2002, 45, 1172-1181.	2.9	153
308	Elevated post-prandial free fatty acids are associated with cardiac sympathetic overactivity in Type II diabetic patients. <i>Diabetologia</i> , 2002, 45, 1737-1738.	2.9	21
309	Effects of surgical menopause and estrogen replacement therapy on atrio-ventricular conduction and ventricular repolarization. <i>Maturitas</i> , 2001, 40, 47-51.	1.0	6
310	The obese Etruscan. <i>Journal of Endocrinological Investigation</i> , 2001, 24, 206-206.	1.8	0
311	“The visceral fat of Bek, Pharaoh’s sculptor” <i>Journal of Endocrinological Investigation</i> , 2001, 24, 836-836.	1.8	0
312	Elevated plasma fatty acid concentrations prolong cardiac repolarization in healthy subjects. <i>American Journal of Clinical Nutrition</i> , 2001, 73, 27-30.	2.2	32
313	Reply to MR Goldstein. <i>American Journal of Clinical Nutrition</i> , 2001, 74, 272-273.	2.2	0
314	High glucose induces ventricular instability and increases vasomotor tone in rats. <i>Diabetologia</i> , 2001, 44, 464-470.	2.9	57
315	Erectile and endothelial dysfunction in Type II diabetes: a possible link. <i>Diabetologia</i> , 2001, 44, 1155-1160.	2.9	140
316	Pizza and Vegetables Don’t Stick to the Endothelium. <i>Circulation</i> , 2001, 104, E34-5.	1.6	15
317	Acute Hyperglycemia and Autonomic Function. <i>Diabetes Care</i> , 2001, 24, 2016-2017.	4.3	9
318	Role of Free Fatty Acids on Cardiac Autonomic Nervous System in Noninsulin-Dependent Diabetic Patients: Effects of Metabolic Control. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2769-2774.	1.8	83
319	The BB-Paraoxonase Genotype Is Associated with Impaired Brachial Reactivity after Acute Hypertriglyceridemia in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1078-1082.	1.8	20
320	Acute hyperglycemia induces an oxidative stress in healthy subjects. <i>Journal of Clinical Investigation</i> , 2001, 108, 635-636.	3.9	191
321	Hyperglycemia and QT interval: time for re-evaluation. <i>Diabetes, Nutrition & Metabolism</i> , 2001, 14, 63-5.	0.4	18
322	The toxic trio: acute, chronic, and post-prandial hyperglycemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2001, 11, 80-3.	1.1	6
323	The effect of acute hyperglycaemia on QTc duration in healthy man. <i>Diabetologia</i> , 2000, 43, 571-575.	2.9	196
324	Hemodynamic effects of acute hyperglycemia in type 2 diabetic patients. <i>Diabetes Care</i> , 2000, 23, 658-663.	4.3	88

#	ARTICLE	IF	CITATIONS
325	Circulating Adhesion Molecules in Humans. <i>Circulation</i> , 2000, 101, 2247-2251.	1.6	208
326	Stress hyperglycaemia and death after myocardial infarction. <i>Lancet, The</i> , 2000, 355, 1647.	6.3	2
327	Hypertension and ascorbic acid. <i>Lancet, The</i> , 2000, 355, 1272-1273.	6.3	7
328	Hyperglycemia leads to ECG reevaluation. <i>Aging Clinical and Experimental Research</i> , 2000, 12, 246-248.	1.4	0
329	Correspondence. <i>Atherosclerosis</i> , 2000, 149, 223-224.	0.4	15
330	Dietary antioxidants for cardiovascular prevention. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2000, 10, 38-44.	1.1	83
331	Impairment of Endothelial Functions by Acute Hyperhomocysteinemia and Reversal by Antioxidant Vitamins. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 2113.	3.8	246
332	Hemorheological and cardiovascular effects of exercise training in the rehabilitation of elderly patients with chronic obstructive pulmonary disease. <i>Archives of Gerontology and Geriatrics</i> , 1999, 28, 1-8.	1.4	2
333	Advancing age and insulin resistance: new facts about an ancient history. <i>European Journal of Clinical Investigation</i> , 1999, 29, 758-769.	1.7	100
334	Mean arterial blood pressure and serum levels of the molar ratio of insulin-like growth factor-1 to its binding protein-3 in healthy centenarians. <i>Journal of Hypertension</i> , 1999, 17, 67-73.	0.3	18
335	QTc Dispersion, Hyperglycemia, and Hyperinsulinemia. <i>Circulation</i> , 1999, 100, e149.	1.6	5
336	Lowering fatty acids potentiates acute insulin response in first degree relatives of people with Type II diabetes. <i>Diabetologia</i> , 1998, 41, 1127-1132.	2.9	83
337	Effect of metformin on food intake in obese subjects. <i>European Journal of Clinical Investigation</i> , 1998, 28, 441-446.	1.7	115
338	Hemodynamic and Metabolic Effects of Transdermal Clonidine in Patients With Hypertension and Non-Insulin-Dependent Diabetes Mellitus. <i>American Journal of Hypertension</i> , 1998, 11, 184-189.	1.0	14
339	Effects of Perindopril and Carvedilol on Endothelium-Dependent Vascular Functions in Patients With Diabetes and Hypertension. <i>Diabetes Care</i> , 1998, 21, 631-636.	4.3	66
340	Antioxidants and Nitrate Tolerance. <i>Circulation</i> , 1998, 98, 1350-1353.	1.6	5
341	Response to Cantero. <i>Diabetes Care</i> , 1998, 21, 327-327.	4.3	0
342	Oxidative Stress and Cardiovascular Complications of Diabetes. , 1998, 14, 78-90.		0

#	ARTICLE	IF	CITATIONS
343	Reply to Elhadd et al. Diabetes Care, 1997, 20, 1338-1339.	4.3	1
344	Metabolic and Cardiovascular Effects of Carvedilol and Atenolol in Non-Insulin-Dependent Diabetes Mellitus and Hypertension. Annals of Internal Medicine, 1997, 126, 955.	2.0	260
345	Peripheral Diabetic Neuropathy. Drugs, 1997, 54, 414-421.	4.9	44
346	L-arginine but not d-arginine stimulates insulin-mediated glucose uptake. Metabolism: Clinical and Experimental, 1997, 46, 1068-1073.	1.5	35
347	The vascular effects of L-Arginine in humans. The role of endogenous insulin.. Journal of Clinical Investigation, 1997, 99, 433-438.	3.9	146
348	L-arginine for testing endothelium-dependent vascular functions in health and disease.. American Journal of Physiology - Endocrinology and Metabolism, 1997, 273, E606.	1.8	27
349	Hyperglycemia Counterbalances the Antihypertensive Effect of Glutathione in Diabetic Patients: Evidence Linking Hypertension and Glycemia Through the Oxidative Stress in Diabetes Mellitus. Journal of Diabetes and Its Complications, 1997, 11, 250-255.	1.2	33
350	Effect of insulin on blood rheology in non-diabetic subjects and in patients with type 2 diabetes mellitus. , 1997, 14, 959-963.		17
351	Effect of insulin on blood rheology in non-diabetic subjects and in patients with type 2 diabetes mellitus. Diabetic Medicine, 1997, 14, 959-963.	1.2	3
352	Vascular Effects of Acute Hyperglycemia in Humans Are Reversed by L-Arginine. Circulation, 1997, 95, 1783-1790.	1.6	300
353	Oxidative Stress and Diabetic Vascular Complications. Diabetes Care, 1996, 19, 257-267.	4.3	1,644
354	Pharmacokinetic-Pharmacodynamic Relationships of Acarbose. Clinical Pharmacokinetics, 1996, 30, 94-106.	1.6	72
355	The involvement of the opioid system in human obesity: a study in normal weight relatives of obese people.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 713-718.	1.8	44
356	Does treatment of noninsulin-dependent diabetes mellitus reduce the risk of coronary heart disease?. Current Opinion in Lipidology, 1996, 7, 227-233.	1.2	6
357	Oxidative stress and insulin action: is there a relationship?. Diabetologia, 1996, 39, 357-363.	2.9	244
358	Metformin Improves Hemodynamic and Rheological Responses to L-Arginine in NIDDM Patients. Diabetes Care, 1996, 19, 934-939.	4.3	69
359	Oxidative stress and insulin action: is there a relationship?. Diabetologia, 1996, 39, 357-363.	2.9	31
360	The involvement of the opioid system in human obesity: a study in normal weight relatives of obese people. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 713-718.	1.8	19

#	ARTICLE	IF	CITATIONS
361	Acetyl-L-carnitine for symptomatic diabetic neuropathy. <i>Diabetologia</i> , 1995, 38, 123-123.	2.9	39
362	Abnormal Rheologic Effects of Glyceryl Trinitrate in Patients with Non-Insulin-Dependent Diabetes Mellitus and Reversal by Antioxidants. <i>Annals of Internal Medicine</i> , 1995, 123, 338.	2.0	31
363	Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1995, 268, E1167-E1173.	1.8	73
364	Chronic intake of pharmacological doses of vitamin E might be useful in the therapy of elderly patients with coronary heart disease. <i>American Journal of Clinical Nutrition</i> , 1995, 61, 848-852.	2.2	41
365	Tolrestat in the Primary Prevention of Diabetic Neuropathy. <i>Diabetes Care</i> , 1995, 18, 536-541.	4.3	36
366	Hyperinsulinemia in offspring of non-insulin-dependent diabetes mellitus patients: The role played by abnormal clearance of insulin. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 1278-1282.	1.5	8
367	Diabetes mellitus, hypertension, and cardiovascular disease: Which role for oxidative stress?. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 363-368.	1.5	317
368	Influence of ozone on haemoglobin oxygen affinity in type-2 diabetic patients with peripheral vascular disease: in vitro studies. <i>Diabète & Métabolisme</i> , 1995, 21, 252-5.	0.3	12
369	Plasma vitamin C affects glucose homeostasis in healthy subjects and in non-insulin-dependent diabetics. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1994, 266, E261-E268.	1.8	63
370	The Squatting Test: A Useful Tool to Assess Both Parasympathetic and Sympathetic Involvement of the Cardiovascular Autonomic Neuropathy in Diabetes. <i>Diabetes</i> , 1994, 43, 607-612.	0.3	40
371	Hemorheological and cardiovascular responses to beta-endorphin and naloxone in healthy subjects and in patients with essential hypertension.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 826-830.	1.8	2
372	Detection of Early Sympathetic Cardiovascular Neuropathy by Squatting Test in NIDDM. <i>Diabetes Care</i> , 1994, 17, 149-151.	4.3	11
373	Evidence for a relationship between oxidative stress and insulin action in non-insulin-dependent (type 2) diabetes mellitus. <i>Diabetes Care</i> , 1994, 17, 1078-1083.	1.5	118
374	Hyperinsulinemia in glucose intolerance: Is it true?. <i>Journal of Endocrinological Investigation</i> , 1994, 17, 391-396.	1.8	1
375	Plasma Endothelin in Diabetic Autonomic Neuropathy. <i>Diabetes Care</i> , 1994, 17, 161-162.	4.3	3
376	The squatting test. A useful tool to assess both parasympathetic and sympathetic involvement of the cardiovascular autonomic neuropathy in diabetes. <i>Diabetes</i> , 1994, 43, 607-612.	0.3	11
377	Medical hypothesis: cardiovascular complications of diabetes mellitus-from glucose to insulin and back. <i>Diabète & Métabolisme</i> , 1994, 20, 445-53.	0.3	5
378	Diabetes mellitus and hypertension: the possible role of hyperglycaemia through oxidative stress. <i>Diabetologia</i> , 1993, 36, 265-266.	2.9	75

#	ARTICLE	IF	CITATIONS
379	Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. <i>European Journal of Clinical Pharmacology</i> , 1993, 44, 107-112.	0.8	164
380	Hyperinsulinemia in hypertension: Increased secretion, reduced clearance or both?. <i>Journal of Endocrinological Investigation</i> , 1993, 16, 315-321.	1.8	13
381	Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women. <i>Diabetes Care</i> , 1993, 16, 1387-1390.	4.3	210
382	Daily Vitamin E Supplements Improve Metabolic Control But Not Insulin Secretion in Elderly Type II Diabetic Patients. <i>Diabetes Care</i> , 1993, 16, 1433-1437.	4.3	155
383	Comparison of Nitrendipine and Cilazapril in Patients With Hypertension and Non-Insulin-Dependent Diabetes Mellitus. <i>American Journal of Hypertension</i> , 1993, 6, 927-932.	1.0	12
384	Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. <i>American Journal of Clinical Nutrition</i> , 1993, 57, 650-656.	2.2	299
385	Combination Therapy in NIDDM. <i>Diabetes Care</i> , 1993, 16, 1625-1626.	4.3	0
386	Respiratory Function in IDDM Patients. <i>Diabetes Care</i> , 1993, 16, 851-852.	4.3	3
387	Tolrestat for Mild Diabetic Neuropathy: A 52-Week, Randomized, Placebo-Controlled Trial. <i>Annals of Internal Medicine</i> , 1993, 118, 7.	2.0	51
388	Coronary artery disease in type-2 diabetes mellitus: a scintigraphic study. <i>Diabète & Métabolisme</i> , 1993, 19, 463-6.	0.3	5
389	The combination of insulin and oral hypoglycaemic drugs: a continuous challenge. <i>Diabète & Métabolisme</i> , 1993, 19, 219-24.	0.3	3
390	Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide. <i>Diabète & Métabolisme</i> , 1993, 19, 225-9.	0.3	12
391	Is a family history of diabetes associated with an increased level of cardiovascular risk factors? Studies in healthy people and in subjects with different degree of glucose intolerance. <i>Diabète & Métabolisme</i> , 1993, 19, 230-8.	0.3	3
392	Decreased insulin clearance as a feature of essential hypertension.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 74, 144-149.	1.8	25
393	Impaired Glucose Metabolism and Reduced Insulin Clearance in Elderly Hypertensives. <i>American Journal of Hypertension</i> , 1992, 5, 345-353.	1.0	19
394	Glutathione Infusion Potentiates Glucose-Induced Insulin Secretion in Aged Patients With Impaired Glucose Tolerance. <i>Diabetes Care</i> , 1992, 15, 1-7.	4.3	52
395	New Insights on Non-enzymatic Glycosylation May Lead to Therapeutic Approaches for the Prevention of Diabetic Complications. <i>Diabetic Medicine</i> , 1992, 9, 297-299.	1.2	119
396	Isolated Fatty Change of Liver as Marker of Glucose Intolerance. <i>Diabetes Care</i> , 1992, 15, 1438-1439.	4.3	0

#	ARTICLE	IF	CITATIONS
397	Calcitonin in painful diabetic neuropathy. <i>Lancet, The</i> , 1992, 339, 746-747.	6.3	27
398	Physiological elevations of plasma β -endorphin alter glucose metabolism in obese, but not normal-weight, subjects. <i>Metabolism: Clinical and Experimental</i> , 1992, 41, 184-190.	1.5	16
399	Height and glucose tolerance. <i>Diabetologia</i> , 1992, 35, 698-699.	2.9	4
400	Nicardipine does not cause deterioration of glucose homeostasis in man: A placebo controlled study in elderly hypertensives with and without diabetes mellitus. <i>European Journal of Clinical Pharmacology</i> , 1992, 43, 39-45.	0.8	11
401	Opioid peptides and obesity. <i>The European Journal of Medicine</i> , 1992, 1, 90-6.	0.1	1
402	Clinical remission in patients with IDDM and family history of NIDDM. <i>Lancet, The</i> , 1991, 337, 1165.	6.3	4
403	Pulsatile Insulin Delivery has Greater Metabolic Effects than Continuous Hormone Administration in Man: Importance of Pulse Frequency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 607-615.	1.8	100
404	Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. <i>Metabolism: Clinical and Experimental</i> , 1991, 40, 902-907.	1.5	56
405	The combined insulin and sulfonylurea therapy in diabetes of elderly people. <i>Archives of Gerontology and Geriatrics</i> , 1991, 13, 245-253.	1.4	3
406	Metabolic Control May Influence the Increased Superoxide Generation in Diabetic Serum. <i>Diabetic Medicine</i> , 1991, 8, 540-542.	1.2	115
407	Anti-oxidants show an anti-hypertensive effect in diabetic and hypertensive subjects. <i>Clinical Science</i> , 1991, 81, 739-742.	1.8	143
408	Hormonal and Metabolic Effects of Beta-Endorphin in the Elderly. <i>Hormone and Metabolic Research</i> , 1991, 23, 351-352.	0.7	0
409	A Role for Beta-Endorphin in the Pathogenesis of Human Obesity?. <i>Hormone and Metabolic Research</i> , 1991, 23, 251-256.	0.7	19
410	Vitamin E Reduction of Protein Glycosylation in Diabetes: New Prospect for Prevention of Diabetic Complications?. <i>Diabetes Care</i> , 1991, 14, 68-72.	4.3	260
411	Persistence of altered metabolic responses to beta-endorphin after normalization of body weight in human obesity. <i>European Journal of Endocrinology</i> , 1991, 124, 159-165.	1.9	14
412	Restoration of sensitivity to sulfonylurea after strict glycaemic control with insulin in non-obese type 2 diabetic subjects. <i>Diabète & Métabolisme</i> , 1991, 17, 443-7.	0.3	9
413	Sensorimotor evaluation of ano-rectal complex in diabetes mellitus. <i>Diabète & Métabolisme</i> , 1991, 17, 520-4.	0.3	4
414	The Role of Hyperglycaemia-Induced Alterations of Antithrombin III and Factor X Activation in the Thrombin Hyperactivity of Diabetes Mellitus. <i>Diabetic Medicine</i> , 1990, 7, 343-348.	1.2	17

#	ARTICLE	IF	CITATIONS
415	Effects of oxytocin upon the endocrine pancreas secretion and glucose turnover in normal man. <i>European Journal of Endocrinology</i> , 1990, 123, 504-510.	1.9	11
416	Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. <i>Diabetologia</i> , 1990, 33, 163-167.	2.9	55
417	Non-enzymatic glycation reduces heparin cofactor II anti-thrombin activity. <i>Diabetologia</i> , 1990, 33, 205-207.	2.9	31
418	Evidence for a Reduced Heparin Cofactor II Biological Activity in Diabetes. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1990, 20, 357-361.	0.5	2
419	Possible Role for Increased C4b-Binding Protein Level in Acquired Protein S Deficiency in Type I Diabetes. <i>Diabetes</i> , 1990, 39, 447-449.	0.3	17
420	Atypical environmental factor in expressing type I (insulin-dependent) diabetes mellitus. <i>Journal of Endocrinological Investigation</i> , 1990, 13, 79-79.	1.8	0
421	Hydroxychloroquine in Decompensated, Treatment-Refractory Noninsulin-Dependent Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 1990, 112, 678.	2.0	126
422	Possible role for increased C4b-binding-protein level in acquired protein S deficiency in type I diabetes. <i>Diabetes</i> , 1990, 39, 447-449.	0.3	5
423	Analysis of diabetic family connection in subjects with insulin-dependent diabetes mellitus (IDDM). <i>Diabète & Métabolisme</i> , 1990, 16, 449-52.	0.3	2
424	Moderate coffee consumption seems to cause no danger for coronary heart disease. <i>Diabète & Métabolisme</i> , 1990, 16, 525-6.	0.3	0
425	Low molecular weight heparin restores antithrombin III activity from hyperglycemia induced alterations. <i>Diabète & Métabolisme</i> , 1990, 16, 86-92.	0.3	2
426	Evidence for a possible role of oxygen free radicals in the abnormal functional arterial vasomotion in insulin dependent diabetes. <i>Diabète & Métabolisme</i> , 1990, 16, 318-22.	0.3	13
427	Protein C deficiency in insulin-dependent diabetes: a hyperglycemia-related phenomenon. <i>Thrombosis and Haemostasis</i> , 1990, 64, 104-7.	1.8	9
428	Beta-endorphin and islet hormone release in humans: evidence for interference with cAMP. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1989, 257, E361-E366.	1.8	7
429	Hyperglycemia-Conditioned Increase in Alpha-2-Macroglobulin in Healthy Normal Subjects: A Phenomenon Correlated with Deficient Antithrombin III Activity. <i>Acta Haematologica</i> , 1989, 82, 61-63.	0.7	4
430	Effects of Oxytocin Delivery on Counter-Regulatory Hormone Response in Insulin-Dependent (Type 1) Diabetic Subjects. <i>Hormone Research</i> , 1989, 31, 250-255.	1.8	18
431	Increased alpha2-macroglobulin in diabetes: A hyperglycemia related phenomenon associated with reduced antithrombin III activity. <i>Acta Diabetologica Latina</i> , 1989, 26, 147-154.	0.2	15
432	Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. <i>Metabolism: Clinical and Experimental</i> , 1989, 38, 1162-1163.	1.5	44

#	ARTICLE	IF	CITATIONS
433	Pregnancy as Environmental Factor Precipitating IDDM. <i>Diabetes Care</i> , 1989, 12, 438-440.	4.3	2
434	Pathophysiological study of the non-insulin-dependent phase of type I diabetes mellitus. <i>Acta Diabetologica Latina</i> , 1988, 25, 161-172.	0.2	3
435	Blood glucose may condition factor VII levels in diabetic and normal subjects. <i>Diabetologia</i> , 1988, 31, 889-91.	2.9	87
436	Impaired insulin-induced erythrocyte magnesium accumulation is correlated to impaired insulin-mediated glucose disposal in Type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1988, 31, 910-5.	2.9	66
437	Pharmacological Doses of Oxytocin Affect Plasma Hormone Levels Modulating Glucose Homeostasis in Normal Man. <i>Hormone Research</i> , 1988, 30, 10-16.	1.8	27
438	Altered Metabolic and Hormonal Responses to Epinephrine and β^2 -Endorphin in Human Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988, 67, 238-244.	1.8	24
439	Hyperglycemia Alters the Beta-Cell Sensitivity to β^2 -Endorphin in Noninsulin-Dependent Diabetic Subjects. <i>Hormone and Metabolic Research</i> , 1988, 20, 306-307.	0.7	1
440	Theophylline prevents the inhibitory effect of prostaglandin E 2 on glucose-induced insulin secretion in man. <i>European Journal of Endocrinology</i> , 1988, 118, 187-192.	1.9	1
441	Does a Common Mechanism Induce Diverse Complications of Diabetes?. <i>Diabetes Care</i> , 1988, 11, 372-373.	4.3	5
442	Advantageous Metabolic Effects of Pulsatile Insulin Delivery in Noninsulin-Dependent Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988, 67, 1005-1010.	1.8	42
443	β^2 -Endorphin-Induced Inhibition and Stimulation of Insulin Secretion in Normal Humans Is Glucose Dependent. <i>Diabetes</i> , 1988, 37, 1265-1270.	0.3	16
444	Opiate Addict as Diabetic Patient?. <i>Diabetes Care</i> , 1988, 11, 443-443.	4.3	11
445	Beta-endorphin-induced inhibition and stimulation of insulin secretion in normal humans is glucose dependent. <i>Diabetes</i> , 1988, 37, 1265-1270.	0.3	9
446	Studies on the mechanism of salicylate-induced increase of insulin secretion in man. <i>Diabète & Métabolisme</i> , 1988, 14, 431-6.	0.3	4
447	Oxytocin increases arginine-induced A and B cell secretion in normal man and in diabetic subjects. <i>Diabète & Métabolisme</i> , 1988, 14, 104-7.	0.3	3
448	Hypertension in the elderly is associated with impaired glucose metabolism independently of obesity and glucose intolerance. <i>Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension</i> , 1988, 6, S45-8.	0.1	3
449	A preliminary note on inhibiting effect of alpha-tocopherol (vit. E) on protein glycation. <i>Diabète & Métabolisme</i> , 1988, 14, 40-2.	0.3	5
450	Opioid peptides and metabolic regulation. <i>Diabetologia</i> , 1988, 31, 3-15.	2.9	32

#	ARTICLE	IF	CITATIONS
451	Î²-Endorphin Infusion Restores Acute Insulin Responses to Glucose in Type-2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 64, 944-948.	1.8	24
452	Hyperglycemia and Obesity as Determinants of Glucose, Insulin, and Glucagon Responses to Î²-Endorphin in Human Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 64, 1122-1128.	1.8	27
453	Induced Hyperglycemia Alters Antithrombin III Activity but not its Plasma Concentration in Healthy Normal Subjects. <i>Diabetes</i> , 1987, 36, 320-323.	0.3	36
454	Dual Effect of Beta-Endorphin on Insulin Secretion in Man. <i>Hormone and Metabolic Research</i> , 1987, 19, 502-503.	0.7	22
455	Impaired Glucose Metabolism in Heroin and Methadone Users. <i>Hormone and Metabolic Research</i> , 1987, 19, 430-433.	0.7	47
456	Primary role of glucagon release in the effect of Î²-endorphin on glucose homeostasis in normal man. <i>European Journal of Endocrinology</i> , 1987, 115, 161-169.	1.9	31
457	Sensitivity to Î²-endorphin as a cause of human obesity. <i>Metabolism: Clinical and Experimental</i> , 1987, 36, 974-978.	1.5	35
458	Inhibitory effect of enkephalin on insulin secretion in healthy subjects and in non insulin-dependent diabetic subjects. <i>Metabolism: Clinical and Experimental</i> , 1987, 36, 286-289.	1.5	21
459	Sodium salicylate restores the impaired insulin response to glucose and improves glucose tolerance in heroin addicts. <i>Acta Diabetologica Latina</i> , 1987, 24, 205-212.	0.2	12
460	Aspirin and non-enzymatic glycation. <i>Acta Diabetologica Latina</i> , 1987, 24, 171-172.	0.2	0
461	Induced hyperglycemia alters antithrombin III activity but not its plasma concentration in healthy normal subjects. <i>Diabetes</i> , 1987, 36, 320-323.	0.3	10
462	Beta-endorphin and islet hormone release in type-2 diabetes mellitus the effects of normoglycemia, enkephalin, naloxone and somatostatin. <i>Diab�te & M�tabolisme</i> , 1987, 13, 618-24.	0.3	5
463	Daily rapid blood glucose variations may condition antithrombin III biologic activity but not its plasma concentration in insulin-dependent diabetes. A possible role for labile non-enzymatic glycation. <i>Diab�te & M�tabolisme</i> , 1987, 13, 16-9.	0.3	9
464	Heterogeneity of diabetes mellitus. <i>Diabetologia</i> , 1987, 30, 678-679.	2.9	4
465	Impaired insulin response to glucose but not to arginine in heroin addicts. <i>Journal of Endocrinological Investigation</i> , 1986, 9, 353-357.	1.8	17
466	Heparin Preserves Antithrombin III Biological Activity from Hyperglycemia-Induced Alterations in Insulin-Dependent Diabetics. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1986, 16, 458-464.	0.5	11
467	Acetylsalicylic acid and glucose metabolism in man: is there a role for prostaglandins?. <i>Diabetologia</i> , 1986, 29, 265-265.	2.9	2
468	Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man. <i>Diabetologia</i> , 1986, 29, 644-647.	2.9	92

#	ARTICLE	IF	CITATIONS
469	Impaired insulin secretion in human diabetes mellitus. Effect of pharmacological activation of gamma-aminobutyric acid system. <i>Acta Diabetologica Latina</i> , 1986, 23, 23-28.	0.2	4
470	Metabolic Control May Alter Antithrombin III Activity but Not Its Plasma Concentration in Diabetes: A Possible Role for Nonenzymatic Glycosylation. <i>Diabetes Care</i> , 1986, 9, 32-35.	4.3	25
471	Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up. <i>Diab�te & M�tabolisme</i> , 1986, 12, 315-8.	0.3	12
472	Glycemic control with an artificial pancreas improves insulin responses to both oral and I.V. Glucose in nonobese noninsulin-dependent diabetic subjects. <i>Acta Diabetologica Latina</i> , 1985, 22, 203-213.	0.2	8
473	Influence of labile glucose adducts on glycosylated protein assay by aminophenylboronic acid affinity chromatography: In vivo studies. <i>Acta Diabetologica Latina</i> , 1985, 22, 79-82.	0.2	3
474	Increased Alpha-2-Macroglobulin in Opiate Addicts: Further Evidence of an Alteration in the Coagulation System due to Opiate Addiction. <i>Acta Haematologica</i> , 1985, 73, 117-117.	0.7	3
475	Effects of Salicylate, Tolbutamide, and Prostaglandin E2 on Insulin Responses to Glucose in Noninsulin- Dependent Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1985, 61, 160-166.	1.8	24
476	Normalization by Sodium Salicylate of the Impaired Counterregulatory Glucagon Response to Hypoglycemia in Insulin-dependent Diabetes: A Possible Role for Endogenous Prostaglandins. <i>Diabetes</i> , 1985, 34, 521-525.	0.3	11
477	ENDOGENOUS OPIATES, HEROIN ADDICTION, AND NON-INSULIN-DEPENDENT DIABETES. <i>Lancet, The</i> , 1985, 326, 769-770.	6.3	18
478	SUGAR AND WOUND HEALING. <i>Lancet, The</i> , 1985, 326, 663-665.	6.3	34
479	Normalization by sodium salicylate of the impaired counterregulatory glucagon response to hypoglycemia in insulin-dependent diabetes. A possible role for endogenous prostaglandins. <i>Diabetes</i> , 1985, 34, 521-525.	0.3	7
480	Increased beta-thromboglobulin levels in heroin addicts. <i>Thrombosis and Haemostasis</i> , 1985, 54, 550.	1.8	0
481	Interaction between epinephrine, prostaglandin E, and met-enkephalin in the regulation of insulin release in man. <i>Diab�te & M�tabolisme</i> , 1985, 11, 295-302.	0.3	4
482	Impaired insulin secretion in human diabetes mellitus. Interactions between naloxone, phentolamine and lysine acetylsalicylate upon glucose induced insulin release. <i>Diab�te & M�tabolisme</i> , 1985, 11, 350-8.	0.3	3
483	Mean red blood cell volume, narcotic addiction, and glucose tolerance. <i>Archives of Internal Medicine</i> , 1985, 145, 1530-1.	4.3	1
484	Increased labile hemoglobin glycosylation in opiate addicts: an unclear phenomenon. <i>Diab�te & M�tabolisme</i> , 1985, 11, 189-90.	0.3	0
485	Depressed antithrombin III biological activity in opiate addicts.. <i>Journal of Clinical Pathology</i> , 1984, 37, 1040-1042.	1.0	15
486	Morphine, Opioid Peptides, and Pancreatic Islet Function. <i>Diabetes Care</i> , 1984, 7, 92-98.	4.3	92

#	ARTICLE	IF	CITATIONS
487	The oxygen-release capacity of red blood cells in insulin-dependent diabetics after artificial pancreas. <i>Acta Diabetologica Latina</i> , 1984, 21, 281-286.	0.2	0
488	Non-Enzymatic Glycosylation Reduces Antithrombin III Activity. <i>Thrombosis and Haemostasis</i> , 1984, 52, 363-363.	1.8	10
489	Non-enzymatic glycosylation reduces antithrombin III activity. <i>Thrombosis and Haemostasis</i> , 1984, 52, 363.	1.8	4
490	Rapid decrease of platelet aggregation (ADP- and collagen-induced) and of platelet circulating aggregates by the artificial pancreas in insulin-dependent diabetics. <i>Diabète & Métabolisme</i> , 1984, 10, 31-5.	0.3	0
491	Glycosylated proteins as an indicator of metabolic control in diabetes: evaluation by aminophenylboronic acid affinity chromatography. <i>Acta Diabetologica Latina</i> , 1984, 21, 49-54.	0.2	1
492	Glucose tolerance and hormonal responses in heroin addicts. A possible role for endogenous opiates in the pathogenesis of non-insulin-dependent diabetes. <i>Metabolism: Clinical and Experimental</i> , 1983, 32, 1163-1165.	1.5	52
493	A role for endogenous prostaglandin E in biphasic pattern of insulin release in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1983, 245, E591-E597.	1.8	15
494	Glycosaminoglycans in human diabetes. <i>Diabète & Métabolisme</i> , 1983, 9, 32-4.	0.3	8
495	A Possible Role for γ -Aminobutyric Acid in the Control of the Endocrine Pancreas*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1982, 54, 1145-1149.	1.8	35
496	Glucagon Secretion in Patients with Hypoparathyroidism: Effect of Serum Calcium on Glucagon Release. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1982, 54, 229-232.	1.8	5
497	Hypomagnesemia in Relation to Diabetic Retinopathy. <i>Diabetes Care</i> , 1982, 5, 558-559.	4.3	22
498	Impaired Insulin Secretion in Human Diabetes Mellitus: The Effect of Naloxone-Induced Opiate Receptor Blockade. <i>Diabetes</i> , 1982, 31, 367-370.	0.3	41
499	Haemoglobin A1 in Addicts. <i>Annals of Internal Medicine</i> , 1982, 96, 536.	2.0	6
500	Calcitonin modulation of insulin and glucagon secretion in man. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1982, 242, E206-E213.	1.8	6
501	Impaired insulin secretion in human diabetes mellitus. I. The effect of alpha-adrenergic inhibition. <i>Pharmacological Research Communications</i> , 1982, 14, 217-225.	0.2	10
502	Increased glycosylated haemoglobin A1 in opiate addicts: Evidence for a hyperglycaemic effect of morphine. <i>Diabetologia</i> , 1982, 22, 379.	2.9	32
503	Platelet aggregation after strict metabolic control using the artificial pancreas. <i>Diabetologia</i> , 1982, 23, 545-545.	2.9	10
504	Glycosylated haemoglobin and reticulocyte count in diabetes. <i>Diabetologia</i> , 1982, 22, 223.	2.9	16

#	ARTICLE	IF	CITATIONS
505	Impaired insulin secretion in human diabetes mellitus. The effect of naloxone-induced opiate receptor blockade. <i>Diabetes</i> , 1982, 31, 367-370.	0.3	20
506	Influence of acetylsalicylic acid on glucose turnover in normal man. <i>Diabète & Métabolisme</i> , 1982, 8, 279-82.	0.3	15
507	Thrombocytopenia in heroin users. <i>Blood</i> , 1982, 60, 276.	0.6	1
508	Thrombocytopenia in heroin users [letter]. <i>Blood</i> , 1982, 60, 276-276.	0.6	1
509	Further studies on the significance of circulating platelet aggregates induced by somatostatin in man. <i>Metabolism: Clinical and Experimental</i> , 1981, 30, 172-175.	1.5	8
510	ACETYLSALICYLIC ACID IN DIABETES. <i>Lancet, The</i> , 1981, 317, 560.	6.3	10
511	Effect of calcitonin on plasma glucose, C-peptide, glucagon and growth hormone responses to arginine in insulin-dependent diabetic subjects. <i>Acta Diabetologica</i> , 1981, 18, 235-241.	1.2	4
512	Effects of acetylsalicylic acid on plasma glucose, free fatty acid, betahydroxybutyrate, glucagon and c-peptide responses to salbutamol in insulin-dependent diabetic subjects. <i>Acta Diabetologica</i> , 1981, 18, 27-36.	1.2	3
513	Modulation by verapamil of insulin and glucagon secretion in man. <i>Acta Diabetologica</i> , 1981, 18, 163-171.	1.2	15
514	Impaired insulin secretion in human diabetes mellitus. II. A possible role for prostaglandins. <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> , 1981, 6, 41-50.	1.2	12
515	Prostaglandins and the alpha-cell. <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> , 1981, 6, 283-297.	1.2	11
516	Colchicine and Insulin Secretion in Man. <i>Diabetes</i> , 1981, 30, 1008-1012.	0.3	9
517	Calcitonin, A Diabetogenic Hormone?*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1981, 53, 318-323.	1.8	27
518	Impaired insulin secretion in human diabetes mellitus III. The effect of the serotonin antagonist metergoline. <i>Diabète & Métabolisme</i> , 1981, 7, 231-4.	0.3	0
519	Colchicine and insulin secretion in man. <i>Diabetes</i> , 1981, 30, 1008-1012.	0.3	0
520	Effect of furosemide on insulin and glucagon responses to arginine in normal subjects. <i>Diabetologia</i> , 1980, 18, 293-6.	2.9	9
521	Impairment of insulin secretion in man by nifedipine. <i>European Journal of Clinical Pharmacology</i> , 1980, 18, 395-398.	0.8	156
522	The effects of salbutamol on some metabolic and endocrine patterns of diabetic subjects. <i>Pharmacological Research Communications</i> , 1980, 12, 909-919.	0.2	5

#	ARTICLE	IF	CITATIONS
523	Somatostatin and Insulin secretion in man. <i>Pharmacological Research Communications</i> , 1980, 12, 57-66.	0.2	4
524	Somatostatin and Insulin Secretion in Man. IV. The Role of Calcium. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1980, 51, 1298-1302.	1.8	7
525	CALCITONIN IN DIABETES. <i>Lancet, The</i> , 1980, 315, 653.	6.3	5
526	Plasma C-peptide response to arginine in insulin-dependent diabetic subjects. <i>Journal of Endocrinological Investigation</i> , 1980, 3, 19-23.	1.8	4
527	Somatostatin and insulin secretion in man. III - Lack of interaction with prostaglandins. <i>Il Farmaco; Edizione Scientifica</i> , 1980, 35, 615-20.	0.0	0
528	Circulating platelet aggregates induced by somatostatin in insulin-dependent diabetic subjects. <i>Diabète & Métabolisme</i> , 1980, 6, 245-9.	0.3	0
529	Effects of acetylsalicylic acid on blood glucose, plasma FFA, glycerol, 3-hydroxybutyrate, alanine, C-peptide, glucagon and growth hormone responses to arginine in insulin-dependent diabetics. <i>Diabète & Métabolisme</i> , 1980, 6, 39-46.	0.3	6
530	Acetylsalicylic Acid Restores Acute Insulin Response Reduced by Furosemide in Man. <i>Diabetes</i> , 1979, 28, 841-845.	0.3	30
531	Effects of α - and β -Adrenergic Inhibition and Somatostatin on Plasma Glucose, Free Fatty Acids, Insulin, Glucagon, and Growth Hormone Responses to Prostaglandin E ₁ in Man*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1979, 48, 302-308.	1.8	52
532	Acetylsalicylic acid augments insulin and c-peptide responses to arginine in diabetes mellitus. Prostaglandins, Leukotrienes and Essential Fatty Acids, 1979, 2, 109-110.	1.2	7
533	Hemodynamic effects of somatostatin in insulin-dependent diabetic subjects. <i>Acta Diabetologica Latina</i> , 1979, 16, 331-337.	0.2	0
534	Somatostatin and insulin secretion in man II. The effect of theophylline. <i>Acta Diabetologica Latina</i> , 1979, 16, 353-358.	0.2	4
535	A comparative study of metabolic and hormonal responses to somatostatin and propranolol in man. <i>Acta Diabetologica Latina</i> , 1979, 16, 77-84.	0.2	0
536	Influence of acetylsalicylic acid on plasma glucose, insulin, glucagon, and growth hormone levels following tolbutamide stimulation in man. <i>Metabolism: Clinical and Experimental</i> , 1979, 28, 887-889.	1.5	22
537	Acetylsalicylic acid restores acute insulin response reduced by furosemide in man. <i>Diabetes</i> , 1979, 28, 841-845.	0.3	13
538	Arguments for an inhibiting role of prostaglandin E ₁ on insulin secretion in man. <i>Il Farmaco; Edizione Scientifica</i> , 1979, 34, 157-64.	0.0	0
539	Influence of acetylsalicylic acid on insulin, glucagon and growth hormone responses to glucose and arginine in healthy subjects. <i>Il Farmaco Edizione Pratica</i> , 1979, 34, 131-7.	0.0	2
540	Relationships between growth hormone secretion and microangiopathy in subjects with prediabetes. <i>Il Farmaco; Edizione Scientifica</i> , 1979, 34, 709-15.	0.0	0

#	ARTICLE	IF	CITATIONS
541	Glucose utilization from dialysate in patients on continuous ambulatory peritoneal dialysis (CAPD). <i>International Journal of Artificial Organs</i> , 1979, 2, 119-24.	0.7	38
542	Effect of calcitonin on insulin response to arginine in man. <i>Diabète & Métabolisme</i> , 1979, 5, 213-6.	0.3	5
543	The effect of acetylsalicylic acid on insulin response to glucose and arginine in normal man. <i>Diabetologia</i> , 1978, 14, 359-362.	2.9	45
544	Prostaglandin E1 inhibits glucose-induced insulin secretion in man. <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> , 1978, 1, 165-166.	1.2	21
545	Prostaglandin E1 increases basal glucagon in man. <i>Pharmacological Research Communications</i> , 1978, 10, 813-821.	0.2	7
546	Effect of calcitonin on glucose-stimulated insulin secretion in normal, obese and prediabetic subjects. <i>Il Farmaco Edizione Pratica</i> , 1978, 33, 256-62.	0.0	5
547	Effects of prostaglandin E1 and prostaglandin F2alpha on insulin and glucagon plasma levels during the intravenous glucose tolerance test in man. <i>Diabète & Métabolisme</i> , 1978, 4, 187-91.	0.3	6
548	Effects of vaso-inactive doses of PGA1 and PGE1 on insulin secretion in the rat. <i>Pharmacological Research Communications</i> , 1977, 9, 427-436.	0.2	2
549	In vivo and in vitro experiments on relationships between PGA1 and glucose utilization. <i>Acta Diabetologica Latina</i> , 1976, 13, 40-46.	0.2	1
550	FFAs and QT Intervals in Obese Women with Visceral Adiposity: Effects of Sustained Weight Loss Over 1 Year. , 0, .		15